Your browser doesn't support javascript.
loading
Efficacy, safety and biomarkers of SG001 for patients with previously treated recurrent or metastatic cervical cancer: an open-label, multicenter, phase Ib trial.
Zuo, Jing; Duan, Wei; Zhao, Mingxuan; Chen, Zhendong; Lin, Jie; Shi, Huaqiu; Jiang, Ou; Zhang, Youzhong; Fang, Meiyu; Wang, Li; Wang, Wei; Huang, Yong; Yu, Junyan; Zhang, Xiaoxue; Pu, Weiqing; Hao, Deshun; She, Fenglin; Yang, Xiugao; Chen, Ying; Tang, Qizhi; Zhang, Xiao; Niu, Miao; Song, Yan'e; Wu, Lingying.
Affiliation
  • Zuo J; Department of Gynecology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
  • Duan W; Department of Gynecology and Oncology, Beijing Obstetrics and Gynecology Hospital, Beijing, P. R. China.
  • Zhao M; Phase 1 Clinical Trial Center, Anning First People's Hospital, Anning, Yunnan, P. R. China.
  • Chen Z; Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, Anhui, P. R. China.
  • Lin J; Department of Oncology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, P. R. China.
  • Shi H; Department of Oncology, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, P. R. China.
  • Jiang O; Department of Medical Oncology, The Second People's Hospital of Neijiang, Neijiang, Sichuan, P. R. China.
  • Zhang Y; Department of Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong, P. R. China.
  • Fang M; Department of Rare and Head and Neck Oncology, Cancer Hospital of The University of Chinese Academy of Sciences Zhejiang Cancer Hospital, Hangzhou, Zhejiang, P. R. China.
  • Wang L; Department of Gynecology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, P. R. China.
  • Wang W; Department of Gastroenterology and Urology, Hunan Cancer Hospital, Changsha, Hunan, P. R. China.
  • Huang Y; Department of Oncology, The Second People's Hospital of Hefei, Hefei, Anhui, P. R. China.
  • Yu J; Department of Oncology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, P. R. China.
  • Zhang X; Clinical Development Division, CSPC Pharmaceutical Group Co., Ltd. Shijiazhuang, Hebei, P. R. China.
  • Pu W; Clinical Development Division, CSPC Pharmaceutical Group Co., Ltd. Shijiazhuang, Hebei, P. R. China.
  • Hao D; Clinical Development Division, CSPC Pharmaceutical Group Co., Ltd. Shijiazhuang, Hebei, P. R. China.
  • She F; Clinical Development Division, CSPC Pharmaceutical Group Co., Ltd. Shijiazhuang, Hebei, P. R. China.
  • Yang X; Clinical Development Division, CSPC Pharmaceutical Group Co., Ltd. Shijiazhuang, Hebei, P. R. China.
  • Chen Y; Clinical Development Division, CSPC Pharmaceutical Group Co., Ltd. Shijiazhuang, Hebei, P. R. China.
  • Tang Q; Clinical Development Division, CSPC Pharmaceutical Group Co., Ltd. Shijiazhuang, Hebei, P. R. China.
  • Zhang X; Clinical Development Division, CSPC Pharmaceutical Group Co., Ltd. Shijiazhuang, Hebei, P. R. China.
  • Niu M; Clinical Development Division, CSPC Pharmaceutical Group Co., Ltd. Shijiazhuang, Hebei, P. R. China.
  • Song Y; Clinical Development Division, CSPC Pharmaceutical Group Co., Ltd. Shijiazhuang, Hebei, P. R. China.
  • Wu L; Department of Gynecology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
Cancer Commun (Lond) ; 44(9): 1042-1046, 2024 Sep.
Article de En | MEDLINE | ID: mdl-39044367

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Cancer Commun (Lond) Année: 2024 Type de document: Article Pays de publication: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Cancer Commun (Lond) Année: 2024 Type de document: Article Pays de publication: États-Unis d'Amérique